Celerion Collaborates with South Korea to Strengthen Early Phase Clinical Research

Celerion and the Korean Drug Development Fund (KDDF) announced a formal collaboration to provide drug development expertise and support for the emerging drug discovery and development industry in South Korea. The agreement—in the form of a Memorandum of Understanding (MOU)—provides the framework for collaborations of mutual benefit to both organizations. Companies funded by KDDF will have access to Celerion’s experience and expertise in early clinical research and bioanalysis, as well as the global footprint of external partner sites. The collaboration will focus on developing innovative and efficient ways to bring Korean drug discoveries to the global market.

Read the full release here.